Adam joined the Life Sciences team as an Associate in 2016 and focuses on investments in the biopharmaceutical sector. Prior to joining Sofinnova Partners, Adam worked for three years in New York City as an Equity Research Analyst at LifeSci Capital. He specialized in oncology while also covering a broad range of therapeutic approaches and disease indications. His research helped define the market opportunity for the treatment of chronic hyperkalemia, the focus of two companies that were acquired for over $4 billion. Adam has a PhD in Molecular Biology from Princeton University where he studied the dynamics of histone modifications during cell division and upon cell cycle arrest. While at Princeton, Adam led efforts to encourage scientists to consider careers outside of academia and formalized his department’s Career Symposium program. Prior to graduate school he spent two years as a Postbaccalaureate Fellow at the National Institutes of Health.